PT  - JOURNAL ARTICLE
AU  - Etienne Rousseau
AU  - Don Wilson
AU  - Frédéric Lacroix-Poisson
AU  - Andra Krauze
AU  - Kim Chi
AU  - Martin Gleave
AU  - Michael McKenzie
AU  - Scott Tyldesley
AU  - S. Larry Goldenberg
AU  - François Bénard
TI  - A Prospective Study on <sup>18</sup>F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
AID  - 10.2967/jnumed.119.226381
DP  - 2019 Apr 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.119.226381
4099  - http://jnm.snmjournals.org/content/early/2019/04/11/jnumed.119.226381.short
4100  - http://jnm.snmjournals.org/content/early/2019/04/11/jnumed.119.226381.full
AB  - 18F-DCFPyL, a prostate specific membrane antigen targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity and impact on patient management of 18F-DCFPyL in the settings of biochemical recurrence of prostate cancer. Methods: Subjects with prostate cancer and biochemical recurrence post radical prostatectomy/curative intent radiotherapy were included in this prospective study. The subjects underwent 18F-DCFPyL PET/CT imaging. The localisation and number of lesions were recorded. The uptake characteristics of the five most active lesions were measured. A pre- and post-test questionnaire was sent to treating physicians to assess the impact on management. Results: One-hundred and thirty subjects were evaluated. 18F-DCFPyL PET/CT localized recurrent prostate cancer in 60% (PSA ≥0.4 to <0.5), 78% (≥0.5 to <1.0), 72% (≥1.0 to <2.0), and 92% (≥2.0) of cases. Many subjects had few lesions: one lesion (40.8%), two (8.5%), three (4.6%). The number of lesions was significantly related to PSA by ANOVA analysis, but there was a large overlap in the PSA values for number of lesions categories. Total lesion uptake was also significantly related to PSA values. Change in treatment intent occurred in 65.5% of subjects. Disease stage changed in 65.5%. Management plans changed in 87.3% of subjects. Twenty-two subjects reported mild adverse events after the scan; all resolved completely. Conclusion: 18F-DCFPyL PET/CT is safe and sensitive for the localization of biochemical recurrence of prostate cancer. This test improved decision making for referring oncologists and changed management for the majority of subjects.